Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Allergan announced that the Food and Drug Administration (FDA) has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections (cIAI), used in combination with metronidazole, and for complicated urinary tract infections (cUTI), including pyelonephritis.
The approval was supported by data from 2 active-controlled studies evaluating Avycaz in children or infants with cIAI (vs meropenem) and cUTI (vs cefepime), and a single-dose pharmacokinetic study; a total of 128 patients (3 months to <18 years old) were treated with Avycaz.
In the cIAI study, the clinical cure rate at the test-of-cure (TOC) visit in the intent-to-treat (ITT) population was 91.8% in the Avycaz + metronidazole group vs 95.5% in the meropenem group. In the cUTI study, the combined clinical and microbiological response rate at TOC in the microbiological-ITT population was 72.2% in the Avycaz group vs 60.9% in the cefepime group.
Overall, the safety profile for Avycaz was found to be similar in the pediatric and adult trials; no new safety issues were observed in the pediatric population.
Avycaz is supplied as 2g/0.5g strength powder for IV injection in single-use vials.
For more information call (800) 678-1605 or visit Avycaz.com.
This article originally appeared on MPR
